Fig. 4: siRNA@eS-BNVs for in vitro and in vivo gene silencing. | Nature Communications

Fig. 4: siRNA@eS-BNVs for in vitro and in vivo gene silencing.

From: Bioengineered nanovesicles for efficient siRNA delivery through ligand-receptor-mediated and enzyme-controlled membrane fusion

Fig. 4

a, b In vitro Luc silencing efficiency in A549ACE2+-Luc cancer cells treated by siLuc@eS-BNVs+Thr and control groups were monitored by IVIS spectrum (a) and quantification (b) of the bioluminescence intensity (n = 6 independent samples). c RT-qPCR analysis of Luc mRNA in A549ACE2+-Luc cancer cells treated by siRNA@eS-BNVs+Thr (n = 6 independent samples). d Relative bioluminescence of A549ACE2+-Luc cancer cells treated by siLuc@eS-BNVs+Thr (n = 6 independent samples). e, f Images by IVIS spectrum (e) and bioluminescence intensity (f) show in vivo Luc knockdown in A549ACE2+-Luc tumors in animal models at 0, 24, 36 and 48 h after i.v. injection of siLuc@eS-BNVs + Thr (n = 4 independent samples). gLuc mRNA levels expressed in A549ACE2+-Luc tumors examined by RT-qPCR at 48 h after treating with siLuc@eS-BNVs + Thr and control groups (n = 4 independent samples). Avg, average. Data in (b, c, d, f and g) are the mean ± s.d. p-values were determined by one-way ANOVA test in (b, c, d, g) or two-way ANOVA test in (f). ****p < 0.0001, ***p < 0.001, **p < 0.01, *p < 0.05, ns, not significant. Source data are provided in a Source Data file.

Back to article page